Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer.
Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, Fassbender TF, Bronsert P, Nicolay NH, Gratzke C, Bock M, Ruf J, Benndorf M, Grosu AL. Bettermann AS, et al. Among authors: ruf j. Radiother Oncol. 2019 Dec;141:214-219. doi: 10.1016/j.radonc.2019.07.005. Epub 2019 Aug 17. Radiother Oncol. 2019. PMID: 31431366
Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?
Denecke T, Rau B, Hoffmann KT, Hildebrandt B, Ruf J, Gutberlet M, Hünerbein M, Felix R, Wust P, Amthauer H. Denecke T, et al. Among authors: ruf j. Eur Radiol. 2005 Aug;15(8):1658-66. doi: 10.1007/s00330-005-2658-4. Epub 2005 Apr 2. Eur Radiol. 2005. PMID: 15806369 Clinical Trial.
Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference.
Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, Bronsert P, Koeber G, Schilling O, Ruf J, Werner M, Jilg CA, Baltas D, Mix M, Grosu AL. Zamboglou C, et al. Among authors: ruf j. Theranostics. 2019 Apr 13;9(9):2595-2605. doi: 10.7150/thno.32376. eCollection 2019. Theranostics. 2019. PMID: 31131055 Free PMC article.
Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.
Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, Kiefer S, Rischke HC, Reichel K, Schmidt-Hegemann NS, Ilhan H, Chirindel AF, Nicolas G, Henkenberens C, Derlin T, Bronsert P, Mavroidis P, Chen RC, Meyer PT, Ruf J, Grosu AL. Zamboglou C, et al. Among authors: ruf j. Radiother Oncol. 2019 Dec;141:208-213. doi: 10.1016/j.radonc.2019.07.002. Epub 2019 Aug 17. Radiother Oncol. 2019. PMID: 31431386
Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients.
Spohn S, Jaegle C, Fassbender TF, Sprave T, Gkika E, Nicolay NH, Bock M, Ruf J, Benndorf M, Gratzke C, Grosu AL, Zamboglou C. Spohn S, et al. Among authors: ruf j. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2796-2803. doi: 10.1007/s00259-020-04827-6. Epub 2020 Apr 28. Eur J Nucl Med Mol Imaging. 2020. PMID: 32342192 Free PMC article.
Association between gastrin-releasing peptide receptor expression as assessed with [68Ga]Ga-RM2 PET/CT and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer.
Michalski K, Stoykow C, Bronsert P, Juhasz-Böss I, Meyer PT, Ruf J, Erbes T, Asberger J. Michalski K, et al. Among authors: ruf j. Nucl Med Biol. 2020 Jul-Aug;86-87:37-43. doi: 10.1016/j.nucmedbio.2020.05.003. Epub 2020 May 12. Nucl Med Biol. 2020. PMID: 32473549
285 results